Guidelines for Anticoagulation Therapy for Secondary Prevention After Deep Vein Thrombosis

Thrombophilia Testing

June 2011

However, there are a number of individuals who present with an acute venous thrombotic event for whom an acquired risk factor cannot be identified. For these patients, we then go on to perform thrombophilia testing as outlined in this slide. A full thrombophilia assessment would include measures of antithrombin, protein C and protein S deficiencies in addition to genetic testing for factor V Leiden and the prothrombin gene mutation. Both lupus-like anticoagulant testing and antiphospholipid antibody assessment is also warranted.

< Previous Slide

Thrombophilia Testing

Next Slide >

 

Jump to section:

• Introduction
• Independent Risk Factors for Venous Thromboembolism¹
• Thrombophilia Testing
• ACCP Treatment Duration Guidelines²
• Aggressive Thrombophilia²
• Case
• Case
• Recurrence Rate
• ACCP Treatment Duration Guidelines³
• D-Dimer Levels and Risk of Recurrent Venous Thromboembolism⁴
• PROLONG: D-Dimer Testing to Determine Duration of Anticoagulation⁵
• PROLONG: D-Dimer Testing to Determine Duration of Anticoagulation⁵
• Idiopathic VTE
• Residual Vein Thrombosis (RVT) to Assess Optimal Management of DVT: DACUS Study⁶
• Residual Vein Thrombosis (RVT) to Determine Duration of Anticoagulation⁶
• Recurrent VTE by RVT at 3 Months: DACUS Study⁶
• Non-compressed vs. Compressed
• Idiopathic DVT: Take Home Point
• Case (revisited)
• Case (revisited)
• Mortality Risk
• Cumulative Recurrence of DVT vs PE After Incident DVT
• Cumulative Recurrence of DVT vs PE After Incident PE
• Independent Predictors of Death within 7 Days of Venous Thromboembolism Recurrence
• Idiopathic PE – Take Home Points
• References
• Clinical and Laboratory Update in Thrombosis and Anticoagulation
• Questions?